Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study
Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study
Background: prostate cancer (PCa) is the most common male cancer in the United Kingdom and we aimed to identify clinically relevant biomarkers corresponding to stage progression of the disease.
Methods: we used enhanced proteomic profiling of PCa progression using iTRAQ 3D LC mass spectrometry on high-quality serum samples to identify biomarkers of PCa.
Results: we identified 41000 proteins. Following specific inclusion/exclusion criteria we targeted seven proteins of which two were validated by ELISA and six potentially interacted forming an ‘interactome’ with only a single protein linking each marker. This network also includes accepted cancer markers, such as TNF, STAT3, NF-kB and IL6.
Conclusions: our linked and interrelated biomarker network highlights the potential utility of six of our seven markers as a panel for diagnosing PCa and, critically, in determining the stage of the disease. Our validation analysis of the MS-identified proteins found that SAA alongside KLK3 may improve categorisation of PCa than by KLK3 alone, and that TSR1, although not significant in this model, might also be a clinically relevant biomarker.
Larkin, S.E.T.
73ffb031-2115-47e3-a62f-907d687d108f
Johnston, H.H.
363ea8fe-c658-465d-98a4-b274156124e4
Jackson, T.R.
67bb4220-da05-4628-ac9f-275f45e4c499
Jamieson, D.G.
00879272-7a6d-455c-b97d-ae645773b337
Roumeliotis, T.I.
82db08bf-89c0-4f3a-a982-9cc962569a2d
Mockridge, C.I.
327aef17-4837-4f2a-a93b-3d17cd1a7f9f
Michael, A.
47cf9826-08c4-4cff-9c01-be6dd055f1d7
Manousopoulou, A.
9a5e4e75-cea9-4d0b-91c8-0fa2af02632f
Papachristou, E.K.
c9c7c2a0-2a7b-4e62-9074-1300828d8f98
Brown, M.D.
785195da-02f2-46c7-b482-d8c8516f09ff
Clarke, N.W.
0688a57b-eea9-46a1-b6c4-1147bde1adf9
Pandha, H.
46b92aaf-f535-430f-89b4-be1f4f1d5ec1
Aukim-Hastie, C.L.
296c775f-26a7-46c8-bdf0-eec843a10c63
Cragg, M.S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Garbis, S.D.
7067fd19-50c9-4d42-9611-f370289470bd
Townsend, P.A.
89300833-c898-4ae1-a3b2-03214c71da52
29 September 2016
Larkin, S.E.T.
73ffb031-2115-47e3-a62f-907d687d108f
Johnston, H.H.
363ea8fe-c658-465d-98a4-b274156124e4
Jackson, T.R.
67bb4220-da05-4628-ac9f-275f45e4c499
Jamieson, D.G.
00879272-7a6d-455c-b97d-ae645773b337
Roumeliotis, T.I.
82db08bf-89c0-4f3a-a982-9cc962569a2d
Mockridge, C.I.
327aef17-4837-4f2a-a93b-3d17cd1a7f9f
Michael, A.
47cf9826-08c4-4cff-9c01-be6dd055f1d7
Manousopoulou, A.
9a5e4e75-cea9-4d0b-91c8-0fa2af02632f
Papachristou, E.K.
c9c7c2a0-2a7b-4e62-9074-1300828d8f98
Brown, M.D.
785195da-02f2-46c7-b482-d8c8516f09ff
Clarke, N.W.
0688a57b-eea9-46a1-b6c4-1147bde1adf9
Pandha, H.
46b92aaf-f535-430f-89b4-be1f4f1d5ec1
Aukim-Hastie, C.L.
296c775f-26a7-46c8-bdf0-eec843a10c63
Cragg, M.S.
ec97f80e-f3c8-49b7-a960-20dff648b78c
Garbis, S.D.
7067fd19-50c9-4d42-9611-f370289470bd
Townsend, P.A.
89300833-c898-4ae1-a3b2-03214c71da52
Larkin, S.E.T., Johnston, H.H., Jackson, T.R., Jamieson, D.G., Roumeliotis, T.I., Mockridge, C.I., Michael, A., Manousopoulou, A., Papachristou, E.K., Brown, M.D., Clarke, N.W., Pandha, H., Aukim-Hastie, C.L., Cragg, M.S., Garbis, S.D. and Townsend, P.A.
(2016)
Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study.
British Journal of Cancer.
(doi:10.1038/bjc.2016.291).
(PMID:27685442)
Abstract
Background: prostate cancer (PCa) is the most common male cancer in the United Kingdom and we aimed to identify clinically relevant biomarkers corresponding to stage progression of the disease.
Methods: we used enhanced proteomic profiling of PCa progression using iTRAQ 3D LC mass spectrometry on high-quality serum samples to identify biomarkers of PCa.
Results: we identified 41000 proteins. Following specific inclusion/exclusion criteria we targeted seven proteins of which two were validated by ELISA and six potentially interacted forming an ‘interactome’ with only a single protein linking each marker. This network also includes accepted cancer markers, such as TNF, STAT3, NF-kB and IL6.
Conclusions: our linked and interrelated biomarker network highlights the potential utility of six of our seven markers as a panel for diagnosing PCa and, critically, in determining the stage of the disease. Our validation analysis of the MS-identified proteins found that SAA alongside KLK3 may improve categorisation of PCa than by KLK3 alone, and that TSR1, although not significant in this model, might also be a clinically relevant biomarker.
Text
Detection of candidate biomarkers of prostate cancer progression in serum_PMID-27685442.pdf
- Accepted Manuscript
Text
Detection of candidate biomarkers of prostate cancer progression in serum_bjc2016291a.pdf
- Version of Record
More information
Accepted/In Press date: 16 August 2016
e-pub ahead of print date: 29 September 2016
Published date: 29 September 2016
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 400963
URI: http://eprints.soton.ac.uk/id/eprint/400963
ISSN: 0007-0920
PURE UUID: b957401d-eea5-4607-a553-a9a825061ef5
Catalogue record
Date deposited: 30 Sep 2016 14:08
Last modified: 15 Mar 2024 02:57
Export record
Altmetrics
Contributors
Author:
S.E.T. Larkin
Author:
H.H. Johnston
Author:
T.R. Jackson
Author:
D.G. Jamieson
Author:
T.I. Roumeliotis
Author:
C.I. Mockridge
Author:
A. Michael
Author:
A. Manousopoulou
Author:
E.K. Papachristou
Author:
M.D. Brown
Author:
N.W. Clarke
Author:
H. Pandha
Author:
C.L. Aukim-Hastie
Author:
S.D. Garbis
Author:
P.A. Townsend
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics